Medical Oncologist
CION Cancer Clinics
The CDKN2A gene: what it does and why it matters | CION Cancer Clinics
CDKN2A is a gene that acts as a brake on cell division. When one copy is faulty from birth, the risk of melanoma, a cancer of the skin's pigment cells, rises, and in some families so does the risk of pancreatic cancer. Inherited faults in this gene are rare. This page explains what the gene does, what a fault changes, and what it does not mean. At CION Cancer Clinics, our oncologists explain what a gene result means for you and your family, and plan the checks that follow.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does the CDKN2A gene actually do?
- What are p16 and p14ARF, and why do they matter?
- How does a CDKN2A fault turn into a melanoma?
- The words you will meet, in plain language
- Inherited CDKN2A fault or a tumour finding?
- Four things families assume about this gene
- What this page cannot tell you
- Common questions about the CDKN2A gene
The short answer
What does the CDKN2A gene actually do?
CDKN2A is a brake on cell division. It tells a cell to pause before it copies itself, and to stop altogether if something has gone wrong. When one copy of the gene is faulty from birth, that brake is weaker in every cell, and the risk of melanoma and pancreatic cancer rises.
One gene, two instructions
CDKN2A is unusual. The same stretch of DNA is read in two different ways to make two different proteins, called p16 and p14ARF. Both protect the cell, through two separate safety systems. A fault can damage one of them or both, which is part of why families with this gene can look quite different from each other.
Why the skin is affected first
Pigment cells in the skin are exposed to sunlight all their lives, and sunlight damages DNA. A cell that already has a weaker brake has less room for that damage. This is why moles, and melanoma, are the first place a CDKN2A fault usually shows itself.
A CDKN2A fault is not a diagnosis. It is a statement about risk.Inside the gene
What are p16 and p14ARF, and why do they matter?
You may see either name on a report. They are two products of the same gene.
p16, the pause button
p16 blocks the signal that pushes a cell into dividing. Without it, a cell moves on to copy itself even when it should be waiting. Most inherited CDKN2A faults damage this protein.
p14ARF, the alarm
p14ARF helps switch on the cell's own damage alarm when growth signals are too strong. If the alarm fails, a damaged cell is less likely to be stopped or cleared.
What a fault changes
A faulty copy leaves the cell with one working brake instead of two. Nothing happens straight away. The risk comes from what a lifetime of wear can do to the copy that remains.
Most often linked to
- Many moles, some of them unusual in shape
- Melanoma, sometimes more than one
- Pancreatic cancer in some families
How common it is
Inherited CDKN2A faults are rare everywhere. Most families described so far live in Europe, North America and Australia. Studies from India are few and small.
Not sure whether this applies to you?
Ask an oncologistFrom gene to cancer
How does a CDKN2A fault turn into a melanoma?
-
You are born with one faulty copy
One copy came from a parent who carries the fault. The other copy, from the other parent, works normally. Every cell in your body starts life this way.
-
Moles may appear in larger numbers
Many carriers have more moles than usual, and some look irregular. Each mole is a small group of pigment cells that grew and then stopped. Most never cause any harm.
-
The working copy is damaged in one cell
Sunlight, age and ordinary copying errors can knock out the second copy in a single cell. That cell has lost its brake.
-
That cell can grow unchecked
Without a brake, the cell keeps dividing. In the skin this can become a melanoma. In the pancreas it can, less often, become a tumour there.
-
Which is why the risk is not certainty
The inherited fault supplies only the first step. Sun exposure, smoking and chance decide much of the rest, which is why relatives with the same fault can have very different lives.
On your report
The words you will meet, in plain language
- Tumour suppressor gene
- A gene whose job is to stop cells growing out of turn. CDKN2A is one. Faults in it remove a safety check.
- Germline
- Present in every cell from birth, and so it can be passed on. The opposite is somatic, a fault found only inside a tumour.
- Pathogenic variant
- A change in the gene's spelling that is known to break it. This is what people mean by a CDKN2A mutation.
- FAMMM syndrome
- Familial atypical multiple mole melanoma. The name for a family pattern of many unusual moles and melanoma, often linked to this gene.
- Atypical mole
- A mole that is larger, flatter or more uneven in colour than most. It is not cancer, but it is watched.
- Penetrance
- How often a fault actually leads to cancer across everyone who carries it. It is never all of them.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Two very different findings
Inherited CDKN2A fault or a tumour finding?
Inherited fault, from a blood test
CDKN2A loss, from a tumour test
Present in every cell from birth
Found only inside the cancer
Rare, and can run in families
Common in many cancer types
Relatives can be offered testing
Nothing is passed to children
Changes skin checks and screening
May guide treatment choices for the cancer
Commonly believed
Four things families assume about this gene
"Indian skin does not get melanoma, so this gene cannot matter here."
Melanoma is less common in darker skin, but it does happen. In Indian patients it often appears on the soles, palms or under a nail, where it is easy to miss. A carrier still needs checks.
"My tumour report says CDKN2A, so my children have it."
Usually not. Tumours lose CDKN2A very often during their own growth. That change stays inside the cancer. Only a blood or saliva test shows whether a fault was inherited.
"A carrier will certainly get melanoma."
The risk is raised, sometimes substantially, but it is not a certainty. Sun protection and regular skin checks change the picture a great deal.
"Lots of moles means I carry the gene."
Many people have lots of moles for ordinary reasons. The gene is suspected when moles come with melanoma in several relatives, or with pancreatic cancer in the same family.
Being straight with you
What this page cannot tell you
It cannot tell you what your own result means. CDKN2A faults differ from each other, and some are linked to pancreatic cancer more strongly than others. What your specific variant means is a question for the counsellor who ordered the test.
It cannot tell you your personal risk
Published risk figures come mostly from families outside India, and they vary widely between studies. Your own risk depends on the exact fault, your family history, how much sun you have had and whether you smoke. A genetic counsellor can put those together for you.
Who this does not apply to
Most people with moles, or with one relative who had melanoma late in life, do not need a CDKN2A test. If your tumour report mentions CDKN2A, that is a question for your oncologist and the targeted therapy team, not a sign of an inherited fault.
If you are unsure whether your family pattern counts, describe it to the helpline. Someone will tell you honestly whether a referral is worth making.Questions we are asked
Common questions about the CDKN2A gene
Is CDKN2A the same as the melanoma gene?
It is the gene most often found in families with inherited melanoma, but it is not the only one. Others include CDK4, MITF, POT1 and BAP1. Many families with several melanomas have no fault found in any of them, which does not mean the history is ignored.
Which cancers are linked to a CDKN2A fault?
Melanoma is the main one, followed by pancreatic cancer in some families. A few studies suggest a raised risk of other cancers too, especially in people who smoke, but that evidence is less settled. Your counsellor will tell you which risks apply to your family.
Can a man carry and pass on a CDKN2A fault?
Yes. The gene is not on a sex chromosome, so men and women carry and pass it on in exactly the same way. Each child of a carrier has an even chance of inheriting it, whichever parent it comes from.
Who in the family should be tested first?
Wherever possible, the relative who has had melanoma or pancreatic cancer. Testing that person first shows whether there is a fault to look for. If they test negative, testing well relatives usually adds little.
Does sun protection really make a difference?
For carriers it is one of the few things that directly lowers risk. Shade, covering clothes, a hat and sunscreen all help. It matters most for children in the family, whether or not they have been tested yet.
Should my children be tested?
Testing is usually offered once a child is old enough to take part in the decision. Sun protection and learning to check their own skin can start well before then. Your counsellor will explain how families in your situation usually approach it.
What does variant of uncertain significance mean for CDKN2A?
It means the laboratory found a change and does not yet know whether it matters. It is not a positive result and should not change your care on its own. Ask how you will be told if it is ever reclassified.
Where do I start if melanoma runs in my family?
Write down who had melanoma, pancreatic cancer or any other cancer, and roughly at what age, on both sides. Take that list to your doctor or a genetic counsellor. The CION helpline can point you to the right clinic if you are not sure where to go.
Your Specialists
Meet CION's oncologists. Bring your family history or genetic report to them.
Our medical oncologists see people with a strong family history of cancer, arrange genetic counselling and testing where it fits, and plan the checks that follow.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- MedlinePlus Genetics — CDKN2A gene
- National Cancer Institute — Genetics of Skin Cancer (PDQ) – Health Professional Version
- Cancer Research UK — Risks and causes of melanoma
- National Cancer Institute — Genetic Testing for Inherited Cancer Susceptibility Syndromes
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
CDKN2A mutation: which cancers and what riskHow far a fault raises risk, and for which cancersCDKN2A positive: what happens nextThe first weeks after a positive resultFamilial atypical multiple mole melanoma syndromeThe family pattern this gene is best known forCDK4, MITF and POT1 genesThe rarer melanoma genes, and how they differ
Talk to us
Melanoma in more than one relative?
Tell us who in your family was diagnosed and at what age. We will tell you honestly whether a genetic referral makes sense, and arrange it if it does. One helpline serves every CION centre.